Rhythm Pharmaceuticals Inc RYTM:NASDAQ

Last Price$3.27NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/20/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$3.15 (2)
Ask (Size)$3.28 (71)
Day Low / HighN/A - N/A
Volume483.5 K

Rhythm Pharmaceuticals Doses First Patients in Clinical Trials of Setmelanotide for Treating Genetic Obesity

10:24AM ET 1/13/2022 MT Newswires
Rhythm Pharmaceuticals (RYTM) said Thursday the first patients have been dosed with setmelanotide in a phase 2 trial to treat genetic obesity and in a phase 3 trial evaluating a switch from the daily to a weekly formulation of the drug candidate.

About 500 patients with severe obesity are expected to be enrolled in the phase 2 trial. Results from this trial will have the potential to identify future patient populations and to inform the design of future registrational studies to support label expansion.

Meanwhile, Rhythm said it expects to launch three additional phase 3 trials of setmelanotide this year.

Price: 8.62, Change: +0.06, Percent Change: +0.70